NBIX - CHARLES KEVIN GORMAN At Neurocrine Biosciences Decides to Exercises Options Worth $470K | Benzinga
A substantial insider activity was disclosed on February 14, as GORMAN, Chief Executive Officer at Neurocrine Biosciences (NASDAQ:NBIX), reported the exercise of a large sell of company stock options.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that GORMAN, Chief Executive Officer at Neurocrine Biosciences, a company in the Health Care sector, just exercised stock options worth 5,090 shares of NBIX stock with an exercise price of $39.28.
As of Thursday morning, Neurocrine Biosciences shares are down by 0.0%, with a current price of $131.77. This implies that GORMAN's 5,090 shares have a value of $470,758.
All You Need to Know About Neurocrine Biosciences
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Understanding the Numbers: Neurocrine Biosciences's Finances
Revenue Growth: Over the 3 months period, Neurocrine Biosciences showcased positive performance, achieving a revenue growth rate of 25.05% as of 31 December, 2023. This reflects a substantial ...